End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
176,200 KRW | -0.62% | -2.06% | -12.56% |
May. 24 | Celltrion Receives European Commission Approval of Omlyclo® (CT-P39), the First and Only Omalizumab Biosimilar Approved in Europe | CI |
May. 10 | Celltrion's Q1 Attributable Profit Slumps 86% | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- The company is in a robust financial situation considering its net cash and margin position.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 69.53 times its estimated earnings per share for the ongoing year.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-12.56% | 26.22B | C | ||
+43.36% | 54.64B | B- | ||
-5.31% | 39.92B | B | ||
+37.52% | 38.82B | A | ||
+14.75% | 26.86B | B- | ||
-22.45% | 18.78B | B | ||
+0.04% | 12.16B | B+ | ||
+25.12% | 12.21B | B+ | ||
+26.04% | 11.94B | C+ | ||
-11.83% | 10.74B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- A068270 Stock
- Ratings Celltrion, Inc.